A recent study has shown that evolocumab, an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), robustly reduces levels of LDL cholesterol and decreases the risk of cardiovascular disease in patients with and without diabetes mellitus. When given on top of statins, evolocumab does not induce diabetes mellitus.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shepherd, J. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29, 1220–1226 (2006).
Zhang, X. L. et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 13, 123 (2015).
Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32290-0 (2017).
Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(17)30313-3 (2017).
Dormuth, C. R. et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 348, g3244 (2014).
Kohli, P. et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J. Am. Coll. Cardiol. 65, 402–404 (2015).
Kazi, D. S. et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318, 748–750 (2017).
Fonarow, G. C. et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. http://dx.doi.org/10.1001/jamacardio.2017.2762 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.V. declares no competing interests. G.K.H. has participated in advisory boards for and has received lecture fees (for lectures on lipid-lowering therapy in general) from Amgen, Sanofi-Aventis and Regeneron, and has received lecture fees (for lectures about lipid-lowering therapy in general) from Pfizer.
Rights and permissions
About this article
Cite this article
Verbeek, R., Hovingh, G. Anti-PCSK9 antibodies — beneficial or inducers of diabetes?. Nat Rev Endocrinol 13, 694–695 (2017). https://doi.org/10.1038/nrendo.2017.145
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.145
